Quarterly report [Sections 13 or 15(d)]

Note 10 - Related party transactions (Details Textual)

v3.25.1
Note 10 - Related party transactions (Details Textual) - USD ($)
 3 Months Ended 41 Months Ended
Mar. 18, 2025
Sep. 02, 2024
Aug. 27, 2024
Jan. 30, 2024
Sep. 06, 2023
Nov. 04, 2021
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Aug. 10, 2023
Schedule of Equity Method Investments [Line Items]                        
Common Stock, Shares Outstanding             2,552,429   2,552,429 2,006,028    
Warrants outstanding             1,267,585   1,267,585 1,267,585    
Accrued liabilities             $ 3,324,000   $ 3,324,000 $ 2,773,000    
Accounts payable             2,390,000   2,390,000 1,258,000    
Public Offering [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Common shares issued (in shares)       188,304                
Over-Allotment Option [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Common shares issued upon exercise of stock options       $ 24,561                
Shares Issued, Price Per Share       $ 51.3                
Common Shares [Member] | Public Offering [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Warrants to purchase common shares, number of warrants       188,174                
Supply Agreement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Expenses             0 $ 0 7,100,000      
Accrued liabilities                   $ 0    
Accounts payable             0   $ 0      
Tuspetinib Licensing Agreement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
License Fee, Total           $ 12,500,000            
Payments for License Fee           5,000,000            
Stock Issued During Period, Value, Licensing Fee           $ 7,500,000            
Hanmi Loan Agreement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Loan agreement amount     $ 10,000,000                  
Loan is repayable date     Jan. 31, 2027                  
Interest expense             100,000          
Interest expense paid             $ 0          
Loan interest rate                     6.00%  
Convertible debt conversion   $ 8,500,000                    
Debt Conversion Agreement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Shares Issued, Price Per Share $ 3.7                      
Debt conversion, description             Additionally, pursuant to the Debt Conversion Agreement, the Company and Hanmi agreed that the interest payment associated with the period from December 21, 2024 through March 31, 2025 may be deferred and made on or before the final closing date of a financing, not including the amount being converted pursuant to the Debt Conversion Agreement, totaling $15.0 million ("Capital Raise"), but no later than June 27, 2025. Further, Hanmi, at its sole discretion, can opt to convert the remaining indebtedness amount, or a portion thereof, to Aptose common shares upon the successful completion of the Capital Raise, provided that the amount of Aptose common shares delivered to Hanmi pursuant to such subsequent conversion shall not cause Hanmi to own more than 19.99% of the Company.          
Capital raise, amount $ 15,000,000                      
Convertiable debt amount $ 1,500,000                      
Common shares converted 409,063                      
Hanmi Pharmaceuticals Co., Ltd. [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Number of common shares held           7,190 508,710   508,710      
Future milestone payments           $ 407,500,000            
Proceeds from Issuance of Common Stock         $ 3,000,000              
Shares Issued, Price Per Share             $ 51.3   $ 51.3      
Investment Owned, Balance, Shares           7,190 508,710   508,710      
Warrants to purchase common shares, number of warrants             77,972   77,972      
Payment of supply costs             $ 0 $ 2,600,000        
Hanmi Pharmaceuticals Co., Ltd. [Member] | Public Offering [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Premium share price (as a percent)       11.00%                
Hanmi Pharmaceuticals Co., Ltd. [Member] | Private Placement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Common shares issued (in shares)       70,175                
Shares Issued, Price Per Share       $ 57                
Hanmi Pharmaceuticals Co., Ltd. [Member] | Common Shares [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Number of shares sold         22,281              
Hanmi Pharmaceuticals Co., Ltd. [Member] | Common Shares [Member] | Private Placement [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Warrants to purchase common shares, number of warrants       77,972                
Maximum [Member] | Hanmi Pharmaceuticals Co., Ltd. [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Investment for ownership interest                       $ 7,000,000
Percentage of investment                       19.99%